Distinct phenotypic and urine biological characteristics are seen for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with a history of ulcerative Hunner lesions (UIC) and those ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...